## HB1583

| HB 1583 | TAXATION (reduces | General        | No technical comments   | As amended in the proposed SD 1, this measure        |  |
|---------|-------------------|----------------|-------------------------|--|--|
| HD 1    | credits)          | comments       |                         | will result in a general fund revenue gain           |  |
|         |                   |                |                         | estimated at \$83.3 million for FY 2010 and \$76.1   |  |
|         |                   | See previous   |                         | million FY 2011.                                     |  |
|         |                   | WAM testimony  |                         |  |  |
| Ì       |                   | on Proposed    | ]                       |  |  |
|         |                   | SD1 (March 27) |                         |  |  |
|         |                   |                |                         |  |  |
| 1       |                   |                |                         |  |  |
| HB 1451 | TAXATION (Act 221 | Prefer HD2     | See separate testimony  | If the measure's effective date is July 1, 2009, the | Without the bill, it is assumed that investment  |
| HD2 SD1 | amendments        | version        | submitted for this bill | revenue impacts would be:                            | claimed for credit per year would be \$150       |
|         |                   |                |                         |  | million. With the new law, investment claimed    |
|         |                   | ]              |                         | • \$15.9 million gain for FY10,                      | would be \$56.3 million less in 2009 and \$75    |
|         |                   |                |                         | • \$36.6 million gain in FY11,                       | million less in 2010. Investment for 2011 and    |
|         |                   |                |                         | • \$11.3 million loss in FY12;                       | 2012 would be \$75.0 million (cap at \$100.0     |
| }       | }                 | <b>i</b>       | 1                       | • \$39.4 million loss in FY13;                       | million x 75% utilization). Assumed \$25 million |
|         |                   |                |                         | • \$20.7 million loss in FY14; and                   | investment would move from Act 221 claim to      |
|         |                   |                |                         | • \$15.0 million loss in FY15.                       | Act 88 claim for 2009 and 2010. Revenue loss     |
|         |                   |                | Į.                      |  | of \$15 million per year for FY12 and FY13 due   |
|         |                   |                |                         |  | to 2-year extension of research credit.          |
|         |                   |                |                         |  |  |
|         |                   |                |                         |  |  |

